On Wednesday, the Food and Drug Administration approved Revolution Medicines’ daraxonrasib as a last resort option for adults with metastatic pancreatic adenocarcinoma (PDAC). In late-stage clinical trials, the drug doubled people’s length of survival compared to standard chemotherapy. Daraxonrasib, which will be sold under the brand name Rasonque, is poised to be the first in a new class of medications that can attack a long-elusive target commonly found in pancreatic and other cancers.
Learn more / En savoir plus / Mehr erfahren:
https://www.scoop.it/t/21st-century-innovative-technologies-and-developments/?&tag=Cancer
https://www.scoop.it/topic/21st-century-innovative-technologies-and-developments/?&tag=Research
Your new post is loading...
On Wednesday, the Food and Drug Administration approved Revolution Medicines’ daraxonrasib as a last resort option for adults with metastatic pancreatic adenocarcinoma (PDAC). In late-stage clinical trials, the drug doubled people’s length of survival compared to standard chemotherapy. Daraxonrasib, which will be sold under the brand name Rasonque, is poised to be the first in a new class of medications that can attack a long-elusive target commonly found in pancreatic and other cancers.
Learn more / En savoir plus / Mehr erfahren:
https://www.scoop.it/t/21st-century-innovative-technologies-and-developments/?&tag=Cancer
https://www.scoop.it/topic/21st-century-innovative-technologies-and-developments/?&tag=Research